HK1211921A1 - 抑制劑化合物 - Google Patents
抑制劑化合物Info
- Publication number
- HK1211921A1 HK1211921A1 HK15112642.0A HK15112642A HK1211921A1 HK 1211921 A1 HK1211921 A1 HK 1211921A1 HK 15112642 A HK15112642 A HK 15112642A HK 1211921 A1 HK1211921 A1 HK 1211921A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitor compounds
- inhibitor
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1216017.2A GB201216017D0 (en) | 2012-09-07 | 2012-09-07 | Inhibitor compounds |
PCT/GB2013/052360 WO2014037750A1 (en) | 2012-09-07 | 2013-09-09 | Inhibitor compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1211921A1 true HK1211921A1 (zh) | 2016-06-03 |
Family
ID=47137117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15112642.0A HK1211921A1 (zh) | 2012-09-07 | 2015-12-23 | 抑制劑化合物 |
Country Status (22)
Country | Link |
---|---|
US (6) | US9409907B2 (zh) |
EP (2) | EP2892889B1 (zh) |
JP (2) | JP6216791B2 (zh) |
CN (1) | CN104837829B (zh) |
AU (2) | AU2013311434B2 (zh) |
BR (1) | BR112015004489B1 (zh) |
CA (1) | CA2884006C (zh) |
CY (1) | CY1119714T1 (zh) |
DK (2) | DK3293183T3 (zh) |
ES (2) | ES2742442T3 (zh) |
GB (1) | GB201216017D0 (zh) |
HK (1) | HK1211921A1 (zh) |
HR (1) | HRP20171835T1 (zh) |
HU (1) | HUE036259T2 (zh) |
LT (1) | LT2892889T (zh) |
NO (1) | NO2892889T3 (zh) |
PL (1) | PL2892889T3 (zh) |
PT (1) | PT2892889T (zh) |
RS (1) | RS56750B1 (zh) |
RU (1) | RU2673079C2 (zh) |
SI (1) | SI2892889T1 (zh) |
WO (1) | WO2014037750A1 (zh) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
AU2009225407B2 (en) | 2008-03-21 | 2013-09-05 | The General Hospital Corporation | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
GB201216017D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
PL3035936T3 (pl) | 2013-08-23 | 2019-08-30 | Neupharma, Inc. | Pewne jednostki chemiczne, kompozycje i sposoby |
GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
JP6616934B2 (ja) * | 2014-05-22 | 2019-12-04 | 株式会社 資生堂 | レナリドミドの光学分割方法 |
US10947201B2 (en) | 2015-02-17 | 2021-03-16 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CA2981844A1 (en) | 2015-04-17 | 2016-10-20 | Netherlands Translational Research Center B.V. | Prognostic biomarkers for ttk inhibitor chemotherapy |
KR102601320B1 (ko) * | 2015-05-29 | 2023-11-10 | 데이진 화-마 가부시키가이샤 | 피리도[3,4-d]피리미딘 유도체 및 그 약학적으로 허용되는 염 |
KR102591886B1 (ko) * | 2015-07-21 | 2023-10-20 | 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. | 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용 |
GB201522532D0 (en) * | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
US10544106B2 (en) | 2016-08-15 | 2020-01-28 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US11261182B2 (en) | 2016-11-28 | 2022-03-01 | Teijin Pharma Limited | Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof |
AU2017364807B2 (en) * | 2016-11-28 | 2021-05-13 | Teijin Limited | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof |
GB201709840D0 (en) * | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
AU2018287988A1 (en) * | 2017-06-20 | 2019-10-10 | Breast Cancer Now | Methods and medical uses |
EP3701304B1 (en) | 2017-10-26 | 2022-05-04 | CommScope Connectivity Belgium BVBA | Telecommunications system |
GB201809460D0 (en) | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
GB201809458D0 (en) | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
EP4328229A2 (en) | 2019-10-30 | 2024-02-28 | Genfleet Therapeutics (Shanghai) Inc. | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof |
KR102396930B1 (ko) * | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
CN115916747A (zh) * | 2020-07-01 | 2023-04-04 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
US11912668B2 (en) | 2020-11-18 | 2024-02-27 | Deciphera Pharmaceuticals, Llc | GCN2 and perk kinase inhibitors and methods of use thereof |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2697710A (en) | 1953-01-02 | 1954-12-21 | Burroughs Wellcome Co | Pyrido (2,3-d) pyrimidines and method of preparing same |
US3021332A (en) | 1954-01-04 | 1962-02-13 | Burroughs Wellcome Co | Pyrido (2, 3-d) pyrimidine compounds and method of making |
AU711426B2 (en) | 1994-11-14 | 1999-10-14 | Warner-Lambert Company | 6-aryl pyrido(2,3-d)pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation |
AU2542501A (en) | 2000-01-25 | 2001-08-07 | Warner-Lambert Company | Pyrido(2,3-d)pyrimidine-2,7-diamine kinase inhibitors |
US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
AU6118001A (en) | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
WO2002090360A1 (en) | 2001-05-10 | 2002-11-14 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
US20030105115A1 (en) | 2001-06-21 | 2003-06-05 | Metcalf Chester A. | Novel pyridopyrimidines and uses thereof |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
AU2002353147A1 (en) | 2001-12-13 | 2003-06-30 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
AU2003210388B2 (en) | 2002-03-07 | 2007-05-17 | F. Hoffmann-La Roche Ag | Bicyclic pyridine and pyrimidine P38 Kinase inhibitors |
ATE374201T1 (de) * | 2002-08-06 | 2007-10-15 | Hoffmann La Roche | 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase |
US20040092521A1 (en) | 2002-11-12 | 2004-05-13 | Altenbach Robert J. | Bicyclic-substituted amines as histamine-3 receptor ligands |
PL376751A1 (pl) | 2002-11-12 | 2006-01-09 | Abbott Laboratories | Bicykliczne podstawione aminy jako ligandy receptora histaminowego-3 |
BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
US20050256118A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
DE602006008945D1 (de) | 2005-06-28 | 2009-10-15 | Sanofi Aventis | Isochinolinderivate als inhibitoren von rho-kinase |
AU2006330924B2 (en) * | 2005-12-21 | 2012-03-15 | Abbvie Inc. | Anti-viral compounds |
TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
MX2009006627A (es) | 2006-12-22 | 2009-08-12 | Novartis Ag | Quinazolinas para la inhibicion de pdk1. |
WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
WO2009032694A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
US20100311965A1 (en) * | 2007-12-28 | 2010-12-09 | Carna Biosciences Inc. | 2-aminoquinazoline derivative |
GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
RU2581367C2 (ru) | 2010-03-01 | 2016-04-20 | Джи Ти Икс, ИНК. | Соединения для лечения рака |
GB201011182D0 (en) | 2010-07-02 | 2010-08-18 | Wireless Fibre Systems Ltd | Riser wireless communications system |
WO2012013557A1 (en) * | 2010-07-30 | 2012-02-02 | Nerviano Medical Sciences S.R.L. | Isoxazolo-quinazolines as modulators of protein kinase activity |
ES2377610B1 (es) | 2010-09-01 | 2013-02-05 | Institut Químic de Sarriá CETS Fundació Privada | Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos. |
WO2012052540A1 (en) | 2010-10-21 | 2012-04-26 | Universitaet Des Saarlandes | Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases |
JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環化合物及びその使用 |
CA2817460A1 (en) | 2010-12-17 | 2012-06-21 | F. Hoffmann-La Roche Ag | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
TWI450891B (zh) | 2010-12-29 | 2014-09-01 | Dev Center Biotechnology | 新穎微管蛋白抑制劑 |
BR112013018515B1 (pt) * | 2011-01-26 | 2021-06-29 | Nerviano Medical Sciences S.R.I | Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
US9745191B2 (en) | 2011-04-11 | 2017-08-29 | Saudi Arabian Oil Company | Auto thermal reforming (ATR) catalytic structures |
EP3430907A1 (en) | 2011-07-29 | 2019-01-23 | Medivation Prostate Therapeutics LLC | Treatment of breast cancer |
CA2850394C (en) | 2011-10-12 | 2019-05-21 | University Health Network | Indazole compounds as kinase inhibitors and method of treating cancer with same |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
US20160000787A1 (en) | 2013-02-26 | 2016-01-07 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
KR20160085915A (ko) | 2013-12-06 | 2016-07-18 | 에프. 호프만-라 로슈 아게 | 국소 진행성 또는 전이성 에스트로겐 수용체 양성 유방암을 치료하기 위한 에스트로겐 수용체 조절자 |
GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
JP2017508469A (ja) | 2014-03-11 | 2017-03-30 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | 癌悪性度、予後及び治療に対する反応性の決定 |
JP2017520603A (ja) | 2014-07-14 | 2017-07-27 | シグナル ファーマシューティカルズ,エルエルシー | 置換ピロロピリミジン化合物を使用するがんの治療方法及びその組成物 |
WO2016073771A2 (en) | 2014-11-06 | 2016-05-12 | Ohio State Innovation Foundation | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors |
GB201522532D0 (en) | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
AU2018287988A1 (en) | 2017-06-20 | 2019-10-10 | Breast Cancer Now | Methods and medical uses |
GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
-
2012
- 2012-09-07 GB GBGB1216017.2A patent/GB201216017D0/en not_active Ceased
-
2013
- 2013-09-09 AU AU2013311434A patent/AU2013311434B2/en active Active
- 2013-09-09 EP EP13760106.8A patent/EP2892889B1/en active Active
- 2013-09-09 BR BR112015004489-1A patent/BR112015004489B1/pt active IP Right Grant
- 2013-09-09 RU RU2015112580A patent/RU2673079C2/ru active
- 2013-09-09 DK DK17192253.7T patent/DK3293183T3/da active
- 2013-09-09 SI SI201330829T patent/SI2892889T1/sl unknown
- 2013-09-09 ES ES17192253T patent/ES2742442T3/es active Active
- 2013-09-09 WO PCT/GB2013/052360 patent/WO2014037750A1/en active Application Filing
- 2013-09-09 CA CA2884006A patent/CA2884006C/en active Active
- 2013-09-09 CN CN201380057967.7A patent/CN104837829B/zh active Active
- 2013-09-09 PL PL13760106T patent/PL2892889T3/pl unknown
- 2013-09-09 PT PT137601068T patent/PT2892889T/pt unknown
- 2013-09-09 LT LTEP13760106.8T patent/LT2892889T/lt unknown
- 2013-09-09 NO NO13760106A patent/NO2892889T3/no unknown
- 2013-09-09 EP EP17192253.7A patent/EP3293183B1/en active Active
- 2013-09-09 US US14/426,549 patent/US9409907B2/en active Active
- 2013-09-09 HU HUE13760106A patent/HUE036259T2/hu unknown
- 2013-09-09 ES ES13760106.8T patent/ES2655194T3/es active Active
- 2013-09-09 JP JP2015530495A patent/JP6216791B2/ja active Active
- 2013-09-09 DK DK13760106.8T patent/DK2892889T3/en active
- 2013-09-09 RS RS20171314A patent/RS56750B1/sr unknown
-
2015
- 2015-12-23 HK HK15112642.0A patent/HK1211921A1/zh unknown
-
2016
- 2016-04-06 US US15/091,980 patent/US9834552B2/en active Active
- 2016-04-06 US US15/091,887 patent/US9890157B2/en active Active
-
2017
- 2017-09-22 JP JP2017182377A patent/JP6496376B2/ja active Active
- 2017-11-24 HR HRP20171835TT patent/HRP20171835T1/hr unknown
- 2017-11-27 AU AU2017268488A patent/AU2017268488B2/en active Active
- 2017-12-29 CY CY20171101358T patent/CY1119714T1/el unknown
-
2018
- 2018-01-08 US US15/864,499 patent/US10479788B2/en active Active
-
2019
- 2019-10-10 US US16/598,717 patent/US11046688B2/en active Active
-
2021
- 2021-05-13 US US17/319,231 patent/US11897877B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211921A1 (zh) | 抑制劑化合物 | |
HK1203498A1 (zh) | 四氫吡唑並嘧啶化合物 | |
HK1198761A1 (zh) | 咪唑並吡咯啶酮化合物 | |
EP2804479A4 (en) | METALLOENZYME INHIBITOR COMPOUNDS | |
EP2925129A4 (en) | PRO-NEUROGENIC COMPOUNDS | |
GB201209138D0 (en) | Compounds | |
GB201214750D0 (en) | Compounds | |
GB201215357D0 (en) | Compounds | |
EP2894981A4 (en) | METALLO ENZYME INHIBITOR COMPOUNDS | |
EP2887803A4 (en) | PRO-NEUROGENIC COMPOUNDS | |
EP2804858A4 (en) | COMPOUNDS INHIBITING METALLOENZYMES | |
EP2828262A4 (en) | IMIDAZOTRIAZINONVERBINDUNGEN | |
GB201204985D0 (en) | Compounds | |
GB201204125D0 (en) | Compounds | |
HK1209422A1 (zh) | 抑制劑 | |
GB201209096D0 (en) | Compounds | |
GB201219820D0 (en) | Compounds | |
GB201211019D0 (en) | Inhibitor compounds | |
GB201217310D0 (en) | Compounds | |
TWI561515B (en) | Metalloenzyme inhibitor compounds | |
GB201223429D0 (en) | Compounds | |
GB201220029D0 (en) | Compounds | |
GB201219819D0 (en) | Compounds | |
GB201218799D0 (en) | Compounds | |
GB201218776D0 (en) | Compounds |